(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number
WO 2007/039178 A3

(51) International Patent Classification:
C07D 413/12 (2006.01) *A61K 31/4245* (2006.01)

(21) International Application Number:
PCT/EP2006/009304

(22) International Filing Date:
26 September 2006 (26.09.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05021235.6 29 September 2005 (29.09.2005) EP

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; 174, avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KEIL, Stefanie** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BERNARDELLI, Patrick** [FR/FR]; Aventis Pharma, 13, quai Jules Guesde, 94403 Vitry-sur-Seine Cedex (FR). **URMANN, Matthias** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **MATTER, Hans** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WENDLER, Wolfgang** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **GLIEN, Maike** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **CHANDROSS, Karen** [US/US]; 13 Staudt Court, Somerset, NJ 08873 (US). **LEE, Lan** [US/US]; Box 230, Pluckemin Park (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
13 September 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS



(I)

(57) Abstract: The invention relates to phenyl-[1 ,2,4]-oxadiazol-5-one derivatives with phenyl group in all its stereoisomeric forms and mixtures in any ratio, and its physiologically acceptable salts and tautomeric forms showing PPARdelta agonist activity. What is described are compounds of the formula (I), wherein the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

WO 2007/039178 A3